GuidelineEuropean journal of haematology2020
COVID-19 and thalassaemia: A position statement of the Thalassaemia International Federation.
Guideline in European journal of haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- COVID-19 and thalassaemia: A position statement of the Thalassaemia International Federation.European journal of haematology · 2020Guideline
- Third-generation sequencing technology in the prevention and control of thalassemia: Applications and advances.The Journal of international medical research · 2026Review
- Biology of Anemia: A Public Health Perspective.The Journal of nutrition · 2023Article
- Clinical outcome and humoral immune responses of β-thalassemia major patients with severe iron overload to SARS-CoV-2 infection and vaccination: a prospective cohort study.EClinicalMedicine · 2023Article
- Article
- A Particular Focus on the Prevalence ofInternational journal of molecular sciences · 2023Article
- Epidemiological Surveillance of SARSCov2 in β-Thalassemia Patients in the Last Two Years: Reinfection Rate, Insights and Future Challenges.Mediterranean journal of hematology and infectious diseases · 2023Article
- Adverse Effects of COVID-19 Vaccination in Patients with Transfusion-Dependent Thalassemia: An Observational Study from a Tertiary Care Center in Punjab, India.Acta haematologica · 2023Observational
- Comparing serum ferritin levels during COVID-19 infection and recovery period in pediatric patients with transfusion-dependent thalassemia, a single-center study.Frontiers in medicine · 2023Article
- Impact of IFN-β1a in treatment of a COVID-19 patient with beta thalassemia and diabetes mellitus: A case report.Clinical case reports · 2022Article
- SARS-CoV-2 infection in patients with β-thalassemia: The French experience.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2022Article
- Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies.Vaccines · 2022Article
- Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement.Italian journal of pediatrics · 2022Review
- People having hematological disorders and hypercoagulability state need extra precautions because of the increased risk of thrombosis after COVID-19 vaccination.Frontiers in medicine · 2022Article
- Understanding the impact of COVID-19 pandemic on health-related quality of life amongst Iranian patients with beta thalassemia major: a grounded theory.Primary health care research & development · 2021Article
- Article
- SARS-CoV-2 infection in patients with β-thalassemia: Experience from Lebanon.American journal of hematology · 2021Article
- A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.Orphanet journal of rare diseases · 2021Review
- First report of COVID-19 reinfection in a patient with beta thalassemia major.Clinical case reports · 2021Article
- COVID-19 Mortality in a Pediatric Patient with Hemoglobin SC Disease and Alpha-Thalassemia Trait.Case reports in critical care · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMany patients with haemoglobinopathies, including thalassaemia and sickle cell disease, are at increased risk of developing severe complications from the coronavirus disease 2019 (COVID-19). Although epidemiologic evidence concerning the novel coronavirus (SARS-CoV-2) infection in these patients is currently lacking, the COVID-19 pandemic represents a significant challenge for haemoglobinopathy patients, their families and their attending physicians.
methodsThe present statement summarizes the key challenges concerning the management of haemoglobinopathies, with particular focus on patients with either transfusion-dependent or non-transfusion-dependent thalassaemia, identifies the gaps in knowledge and suggests measures and strategies to deal with the pandemic, based on available evidence and expert opinions. Key areas covered include patients' risk level, adaptation of haemoglobinopathy care, safety of blood transfusions, blood supply challenges, and lifestyle and nutritional considerations.
conclusionsThe proposed measures and strategies may be useful as a blueprint for other disorders which require regular hospital visits, as well as for the timely adaptation of patient care during similar future pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.